Skip to main content
Erschienen in: Wiener klinische Wochenschrift 1/2019

12.04.2019 | leitlinien für die praxis

Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2019)

verfasst von: Thomas C. Wascher, Bernhard Paulweber, Hermann Toplak, Christoph H. Saely, Heinz Drexel, Bernhard Föger, Friedrich Hoppichler, Thomas Stulnig, Harald Stingl, Martin Clodi, den Ausschuss Leitlinien

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass eine medikamentöse Therapie mit Statinen das kardiovaskuläre Risiko von Patienten mit Diabetes senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der Österreichischen Diabetes Gesellschaft zum Einsatz lipidsenkender Medikamente dar.
Fußnoten
1
Ohne zusätzlichen Risikofaktoren oder Endorganerkrankung.
 
2
Mit zusätzlichen Risikofaktoren oder Endorganerkrankung.
 
Literatur
1.
Zurück zum Zitat The Sixth Joint Task Force of the European Society of Cardiology. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.CrossRef The Sixth Joint Task Force of the European Society of Cardiology. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.CrossRef
2.
Zurück zum Zitat Catapano AL, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2016;37:2999–3058.CrossRef Catapano AL, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2016;37:2999–3058.CrossRef
3.
Zurück zum Zitat Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24:91–120.CrossRef Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24:91–120.CrossRef
4.
Zurück zum Zitat Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 trials of statins. Lancet. 2005;366:1267–78.CrossRef Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 trials of statins. Lancet. 2005;366:1267–78.CrossRef
5.
Zurück zum Zitat Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.CrossRef Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.CrossRef
6.
Zurück zum Zitat Cholesterol Treatment Trialists Collaborators. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular diesease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRef Cholesterol Treatment Trialists Collaborators. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular diesease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRef
7.
Zurück zum Zitat Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapie after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRef Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapie after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRef
8.
Zurück zum Zitat Sabatine MA, Giugliano RP, Keech AC, Honarpour N, Wiviott ST, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRef Sabatine MA, Giugliano RP, Keech AC, Honarpour N, Wiviott ST, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRef
10.
Zurück zum Zitat Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.CrossRef Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.CrossRef
11.
Zurück zum Zitat Keech A, Simmes RJ, Barter B, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.CrossRef Keech A, Simmes RJ, Barter B, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.CrossRef
12.
Zurück zum Zitat The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRef The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRef
Metadaten
Titel
Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2019)
verfasst von
Thomas C. Wascher
Bernhard Paulweber
Hermann Toplak
Christoph H. Saely
Heinz Drexel
Bernhard Föger
Friedrich Hoppichler
Thomas Stulnig
Harald Stingl
Martin Clodi
den Ausschuss Leitlinien
Publikationsdatum
12.04.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-1444-2

Weitere Artikel der Sonderheft 1/2019

Wiener klinische Wochenschrift 1/2019 Zur Ausgabe